All articles tagged with #glp 1
A cross-sectional study of 1,904 participants across four countries found that GLP-1 users reported nail detachment at a rate of 39%, compared to 9% of non-users. While the association is strong, researchers caution that weight loss and nutritional deficiencies may be the primary drivers rather than the drugs themselves.
A new study presented at the European Academy of Dermatology and Venereology Congress found that people taking GLP-1 medications for obesity or diabetes are significantly more likely to experience nail detachment and hair loss than non-users. While the association is strong, experts caution that rapid weight loss and nutritional deficiencies may be the primary drivers rather than the drugs themselves.
A pilot study indicates that medically tailored meals and digital wellness apps can significantly reduce weight regain after patients stop GLP-1 medications, with control participants regaining 10.75% of body weight in four months compared to roughly 3.6% for intervention groups.
New preclinical research suggests that obesity leaves a lasting epigenetic 'memory' in fat cells, keeping the hunger hormone asprosin elevated even after weight loss. This mechanism may explain why patients regain weight after stopping GLP-1 medications and why offspring of mothers with obesity face higher susceptibility. While the findings are based on mouse models, they identify a potential therapeutic target for preventing weight rebound.
Two new studies presented at the European Academy of Dermatology and Venereology Congress indicate that users of GLP-1 receptor agonists, such as semaglutide and tirzepatide, experience significantly higher rates of hair loss and nail problems compared to non-users. While the findings show a strong association, experts emphasize that these issues may stem from rapid weight loss and nutritional deficiencies rather than the drugs themselves, and patients should not discontinue treatment without medical advice.
Fitness experts argue that adults over 40 can maintain muscle and mobility with just 10 minutes of daily resistance training, rather than long gym sessions. This approach is particularly relevant for users of GLP-1 weight-loss medications who risk losing lean mass. While some experts emphasize daily consistency, others suggest that two to three sessions per week are sufficient for maintenance.
New non-peer-reviewed studies suggest GLP-1 medications may be associated with increased hair loss and nail detachment, though experts caution that rapid weight loss and nutritional deficiencies likely contribute to these side effects.
Eli Lilly’s experimental triple-agonist retatrutide achieved up to 25% weight loss in non-diabetic adults and 18.8% in those with type 2 diabetes in Phase 3 trials. The drug targets GLP-1, GIP, and glucagon, offering benefits beyond weight loss, including improved knee pain, sleep apnea, and blood sugar control, though gastrointestinal side effects remain common.
Eli Lilly has released new Phase 3 data for its triple-agonist drug retatrutide, showing that even the lowest dose yields significant weight loss, while a new combination therapy, EloraTZP, demonstrates even greater efficacy but with higher dropout rates due to side effects.
Eli Lilly reported that its experimental triple-agonist retatrutide caused an average weight loss of 49.6 pounds in patients with Type 2 diabetes, while a new combination therapy, EloraTZP, achieved up to 54.1 pounds of loss. Both drugs target multiple gut hormones to enhance satiety and metabolic control, with retatrutide expected to seek FDA approval by March 2027.
Eli Lilly has advanced two major obesity treatments: a new amylin-tirzepatide combination and the triple-agonist retatrutide. The combination therapy achieved up to 23.3% weight loss in a Phase 2 trial, while retatrutide reached up to 25% weight loss in Phase 3 trials for obesity and 23% for Type 2 diabetes. Both drugs target multiple gut hormones to enhance satiety and metabolic effects, positioning them as potential alternatives to existing GLP-1 therapies. Lilly plans to file for retatrutide approval early next year and advance the combination therapy to Phase 3 trials by late 2026.
Edward Gillen, a 59-year-old Massachusetts father and former state highway worker, has filed a lawsuit against Novo Nordisk alleging that the diabetes drug Ozempic caused him to go permanently blind. Gillen, who took the medication for approximately a year to manage diabetes, reported sudden vision loss in May 2025 that progressed to total blindness by June 1. Doctors diagnosed him with nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition described as a 'stroke' of the optic nerve. Gillen is part of a growing wave of over 200 lawsuits in federal court against GLP-1 manufacturers, including Novo Nordisk and Eli Lilly, claiming the drugs caused irreversible vision loss without adequate warning. While Gillen’s community is raising funds for his adaptive training, Novo Nordisk maintains that the lawsuits are without merit and that semaglutide has a well-established safety profile.
Eli Lilly presented detailed phase 3 data for retatrutide and phase 2 results for the experimental combination EloraTZP at the European Association for the Study of Diabetes in Milan. Retatrutide, a triple-agonist, achieved 20.8% average weight loss at the top dose, while EloraTZP, combining amylin and tirzepatide, reached 23.3% weight loss. Lilly plans to file for retatrutide approval in early 2027 and advance EloraTZP to phase 3 trials by year-end.
Eli Lilly reported that its experimental combination of the amylin-targeting drug eloralintide and its existing GLP-1/GIP drug tirzepatide produced superior weight loss in a mid-stage trial. Patients with obesity and Type 2 diabetes lost up to 23.3% of their body weight over 48 weeks, outperforming tirzepatide alone. While the results are promising, higher discontinuation rates due to side effects raised questions about tolerability. Lilly plans to advance the therapy to Phase 3 trials by the end of 2026.
Eli Lilly’s experimental triple-agonist drug retatrutide has demonstrated unprecedented weight-loss results in two major Phase 3 trials, with participants losing up to 25% of their body weight. The drug, which targets three gut hormones, also significantly improved blood sugar control and cardiometabolic markers, though it carries gastrointestinal side effects similar to existing GLP-1 medications.